At the beginning of the week s hares of Novocure catapulted up as high as 50 percent  

Such impressive result was due to the announcement of positive test results from experimental cancer treatment.

The cancer research and treatment company has been experimenting with proprietary cancer therapies that utilize electrical fields.

Results from phase 3 pivotal EF-14 trial showed a consistent and maintained improvement in overall survival at two-to-five year marks.The trial added Novocure’s Optune treatment to standard temozolomide chemotherapy to treat newly diagnosed Glioblastoma, a common form of brain cancer.

Source: CNBC